Haematological Malignancies

Single dose growth factor comparable to daily dose

19/02/2010 | A single dose of pegfilgrastim administered once per chemotherapy cycle is comparable to daily injections of filgrastim and may be more beneficial for paediatric sarcoma patients receiving myelosuppressive chemotherapy, researchers conclude.


Funeral workers have higher risk of leukaemia

26/11/2009 | Funeral industry workers who are exposed to formaldehyde have an increased risk of mortality from myeloid leukaemia, a study finds.


Low-dose dexamethasone better with lenalidomide

22/10/2009 | Lenalidomide plus low-dose dexamethasone is associated with better short-term overall survival and lower toxicity than lenalidomide plus high-dose dexamethasone in patients with newly diagnosed myeloma, a study finds.


Re-vaccination compliance poor

01/10/2009 | Less than half of Australia's young cancer survivors are receiving booster vaccinations post-chemotherapy and are at increased risk of vaccine preventable diseases, researchers find.


Dexamethasone-based therapy improves survival in childhood ALL

10/09/2009 | High survival rates in childhood acute lymphoblastic leukaemia can be achieved with treatment regimens that are associated with few long-term side-effects, including the omission of prophylactic cranial irradiation, a study finds.


Limiting radiation reduces breast cancer risk in Hodgkin's survivors

13/08/2009 | Women treated with radiation therapy for Hodgkin's lymphoma before age 41 are at high risk for breast cancer but a reduction in radiation volume can lower this risk, researchers report.


Stroke in lymphoma linked to radiotherapy

02/07/2009 | Patients treated for Hodgkin lymphoma with radiation therapy were more than twice as likely to suffer from stroke later in life, according a retrospective study by Dutch researchers. 1 comment


No striking improvements from UK cancer plan

24/03/2009 | A cancer plan for England has improved survival rates slightly but the jury is still out on whether the plan is working effectively.


Azacitidine prolongs survival in high-risk myelodysplastic syndrome

06/03/2009 | Azacitidine prolongs overall survival and changes the natural history of myelodysplastic syndrome in patients with higher-risk disease, researchers report.


"Watch and Wait" reasonable option in mantle-cell lymphoma

06/03/2009 | In selected asymptomatic patients with mantle-cell lymphoma deferred initial treatment is an acceptable management approach, according to a retrospective analysis.


More Haematological Malignancies news

Journals

Members of Oncology Update can access the following journals for free:

Most viewed articles this week

Recent comments

Related sites